Molecular correlates of response. Baseline mutations identified using the FoundationOne Heme panel and grouped by responses during phase 2 (A) or phase 1b (B). CRMRD, CR without minimal residual disease; MLFS, morphologic leukemia-free state; NE, not evaluated; PD, progressive disease; PR, partial remission; SD, stable disease; TF, treatment failure.